MiR-181a-driven downregulation of cholesterol biosynthesis through SREBP2 inhibition suppresses uveal melanoma metastasis
miR-181a inhibits UM metastasis by targeting SREBP2 and reducing cholesterol biosynthesis. Its combination with crizotinib may provide a promising therapeutic strategy for metastatic UM.
Authors
- Houda Tahiri (ORCID: https://orcid.org/0000-0001-9565-088X)
- Pierre Hardy (ORCID: https://orcid.org/0009-0007-4824-0504)
- Claudia Gilbert (ORCID: https://orcid.org/0000-0002-2430-8435)
- Solange Landreville (ORCID: https://orcid.org/0000-0002-9164-0657)
- Rui Wang (ORCID: https://orcid.org/0000-0003-3825-3620)
- Chun Yang (ORCID: https://orcid.org/0000-0002-2648-9444)
Institutions
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Hôpital du Saint-Sacrement (CA)
- Université Laval (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1186/s13046-025-03459-8
- Citations
- 1
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Fonds de Recherche du Québec - Santé